Evidence map›Paper›PMID 18991890›Full record

ArticleAnnals of the New York Academy of Sciences2008

Behavioral effects of CB2 cannabinoid receptor activation and its influence on food and alcohol consumption.

E S Onaivi, O Carpio, H Ishiguro, N Schanz, G R Uhl, R Benno

Open access · greenAbstract read
In one paragraph

Article in Annals of the New York Academy of Sciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Hypothalamic endocannabinoids in obesity: an old story with new challenges.Cellular and molecular life sciences : CMLS · 2021
    Review
  16. Article
  17. Article
  18. Article
  19. Endocannabinoids in Body Weight Control.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

E S OnaiviDepartment of Biology, William Paterson University, Wayne, New Jersey, USA. Onaivie@wpunj.edu
O Carpio
H Ishiguro
N Schanz
G R Uhl
R Benno
William Paterson University · USNational Institute on Drug Abuse · USUniversity of Tsukuba · JP

Funding

Genetic Approaches To Characterizing Drug Responses And Vulnerabilities: MiceZIADA000165 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI UHL, GEORGE RICHARD · 2009 to 2016
$7.9M
GENETIC APPROACHES TO CHARACTERIZING DRUG RESPONSES AND VULNERABILITIES: MICEZ01DA000165 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI UHL, GEORGE RICHARD · 1995 to 2008
$1.5M
Intramural NIH HHS Z01 DA000165
6 · The paper itself

Abstract

Consumers of marijuana typically feel a strong, compulsive desire to consume food. Although past research revealed that the CB1 cannabinoid receptor is a potent regulator of food intake, the functional presence of neuronal CB2 cannabinoid receptors in the brain has been controversial. The role of CB2 receptors in food and alcohol consumption and the behavioral effects of CB2 receptor ligands are not well characterized. This is because CB2 cannabinoid receptors were thought to be absent from the brain and expressed primarily in immune cells and in the periphery. We tested the effects of peripheral injections of CB2 antagonist AM 630, CB2 agonist PEA, and CB1 antagonist AM 251 on male C57BL/6, Balb/c, and DBA/2 mice at the beginning of the night cycle and after overnight 12-hour fasts. We also investigated the effects of the putative CB2 agonist, JWH015, and CB2 antagonist, SR144528, in mouse motor function tests and in the two-compartment black and white box. Under standard conditions, the CB2 antagonist AM 630 inhibited food consumption in C57BL/6 mice and DBA/2 mice, but failed to block food intake of Balb/c mice. The CB2 agonist PEA had no significant effect on food consumption in Balb/c mice, and reduced food intake in C57BL/6 and DBA mice. The CB1 antagonist AM 251 inhibited food ingestion in the three mouse strains at variable times. After 12-hour food deprivation, the CB2 antagonist AM 630 increased food consumption in C57Bl/6 mice, but failed to produce significant changes in food intake for Balb/c and DBA/2 mice. The CB2 agonist PEA also reduced food consumption in all three mice strains at variable times. In comparison to the CB2 ligands, CB1 antagonist AM 251 inhibited food ingestion in the mouse strains. A general pattern of depression in locomotor activity was induced by JWH 015 in both males and females in the three mouse strains tested as the dose was increased. The development and enhancement of alcohol preference was observed after chronic treatment with CB2 agonist JWH 015 in stressed mice, but not in controls. In the DBA/2 strain, the spontaneous locomotor activity and stereotype behavior was enhanced by acute administration of low doses of SR144528. There was a reduction in CNR2 gene expression in the ventral mid-brain region of mice that developed alcohol preference, but not in those that did not develop alcohol preference. These effects of CB2 cannabinoid receptor ligands in in vivo behavioral tests are provided as functional evidence that CB2-Rs in the brain play a role in food and alcohol consumption and in the modification of mouse behavior.

Indexed as

Alcohol DrinkingCannabinoidsAnimalsBehavior, AnimalEatingFemaleFood DeprivationLigandsMaleMiceMice, Inbred StrainsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2CannabinoidsLigandsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID18991890
PMCPMC4219871
OpenAlexW1974462296

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.